Title:
TPBG ANTIBODY AND PREPARATION METHOD THEREFOR AND CONJUGATE AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2018/113136
Kind Code:
A1
Abstract:
A TPBG antibody and a preparation method therefor and a conjugate and an application thereof. The TPBG antibody comprises one or more of a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 in a heavy chain variable region of the TPBG antibody, and/or one or more of a light chain CDR1, a light chain CDR2, and a light chain CDR3 in a light chain variable region of the TPBG antibody. An amino acid sequence of the TPBG antibody is further provided. The TPBG antibody is a humanized antibody and has a high affinity, and a conjugate produced after coupling with a small molecule drug toxin MMAF can have a cytotoxic effect on TPBG-positive cells. Therefore, the TPBG antibody is applicable to the preparation of drugs for treating tumors and other drugs.
Inventors:
SUN XIAOLAN (CN)
ZHANG YING (CN)
ZHANG YU (CN)
HU FEIFEI (CN)
GONG SHIYONG (CN)
LIU LILE (CN)
ZHANG YING (CN)
ZHANG YU (CN)
HU FEIFEI (CN)
GONG SHIYONG (CN)
LIU LILE (CN)
Application Number:
PCT/CN2017/079454
Publication Date:
June 28, 2018
Filing Date:
April 05, 2017
Export Citation:
Assignee:
XDCEXPLORER SHANGHAI CO LTD (CN)
International Classes:
C07K16/30; A61K47/00; A61P35/00; C12N5/10; C12N15/13; C12N15/85
Domestic Patent References:
| WO2015177360A1 | 2015-11-26 |
Foreign References:
| CN105288644A | 2016-02-03 | |||
| CN105813655A | 2016-07-27 | |||
| CN101437850A | 2009-05-20 |
Other References:
SAPRA, P. ET AL.: "Long-term Tumor Regression Induced by an Antibody-Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells", MOLECULAR CANCER THERAPEUTICS, vol. 12, no. 1, 5 December 2012 (2012-12-05), pages 38 - 47, XP055197709
LEAL, M. ET AL.: "Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice", BIOCONJUGATE CHEMISTRY, vol. 26, 16 July 2015 (2015-07-16), pages 2223 - 2232, XP055497137
WANG, YUJIE ET AL.: "Antibody-Drug Conjugates: Design and Clinical Progress", ACTA PHARMACEUTICA SINICA, vol. 51, no. 8, 12 August 2016 (2016-08-12), pages 1209 - 1216, XP055497140
LEAL, M. ET AL.: "Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice", BIOCONJUGATE CHEMISTRY, vol. 26, 16 July 2015 (2015-07-16), pages 2223 - 2232, XP055497137
WANG, YUJIE ET AL.: "Antibody-Drug Conjugates: Design and Clinical Progress", ACTA PHARMACEUTICA SINICA, vol. 51, no. 8, 12 August 2016 (2016-08-12), pages 1209 - 1216, XP055497140
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF:
Previous Patent: METHOD FOR ADJUSTING WEARING OF SMART WEARABLE DEVICE
Next Patent: SOLAR DUAL SYSTEM CONTROLLER AND CONTROL CIRCUIT THEREOF
Next Patent: SOLAR DUAL SYSTEM CONTROLLER AND CONTROL CIRCUIT THEREOF